Intrabody Gene Therapy Ameliorates Motor, Cognitive, and Neuropathological Symptoms in Multiple Mouse Models of Huntington's Disease by Southwell, Amber L. et al.
Neurobiology of Disease
Intrabody Gene Therapy Ameliorates Motor, Cognitive, and
Neuropathological Symptoms in Multiple Mouse Models of
Huntington’s Disease
Amber L. Southwell, Jan Ko, and Paul H. Patterson
Division of Biology, California Institute of Technology, Pasadena, California 91125
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease resulting from the expansion of a glutamine repeat in
the huntingtin (Htt) protein. Current therapies are directed at managing symptoms such as chorea and psychiatric disturbances. In an
effort to develop a therapy directed at disease prevention we investigated the utility of highly specific, anti-Htt intracellular antibodies
(intrabodies). We previously showed that VL12.3, an intrabody recognizing the N terminus of Htt, and Happ1, an intrabody recognizing
theproline-richdomainofHtt, both reducemHtt-induced toxicity andaggregation in cell culture andbrain slicemodels ofHD.Due to the
different mechanisms of action of these two intrabodies, we then tested both in the brains of five mouse models of HD using a chimeric
adeno-associated virus 2/1 (AAV2/1) vectorwith amodifiedCMVenhancer/chicken-actinpromoter.VL12.3 treatment,while beneficial
in a lentiviralmodel of HD, has no effect on the YAC128HDmodel and actually increases severity of phenotype andmortality in the R6/2
HDmodel. In contrast, Happ1 treatment confers significant beneficial effects in a variety of assays ofmotor and cognitive deficits. Happ1
also strongly ameliorates the neuropathology found in the lentiviral, R6/2, N171-82Q, YAC128, and BACHD models of HD. Moreover,
Happ1 significantly prolongs the life span of N171-82Q mice. These results indicate that increasing the turnover of mHtt using AAV-
Happ1 gene therapy represents a highly specific and effective treatment in diverse mouse models of HD.
Introduction
Huntington’s disease (HD) results from the expansion of a glu-
tamine repeat in exon 1 (HDx-1) of the huntingtin protein (Htt)
(The Huntington’s Disease Collaborative Research Group,
1993). Although the disease-causing mutation is limited to the
glutamine repeat, the flanking domains modulate toxicity of the
mutant protein (Duennwald et al., 2006). Exon 1 of Htt consists
of 17N-terminal amino acids, the glutamine repeat, two polypro-
line (polyP) domains separated by a proline-rich (P-rich) do-
main [collectively known as the proline-rich region (PRR)], and
13 C-terminal amino acids.
The simple, autosomal dominant nature of HD should allow
for neuroprotective strategies rather than more complicated re-
storative strategies. The therapies currently available to HD pa-
tients are, however, aimed at symptom management rather than
the early stages of the disease. Although HD has a single genetic
cause, it has a very complex pathologywith detrimental effects on
a wide variety of cellular processes. Therefore, it is advantageous
in terms of specificity and efficacy to direct therapy toward the
most upstreamHD targets including themutantHtt (mHtt) pro-
tein itself. One approach of this type is the use of therapeutic
anti-Htt intrabodies (iAbs).
Intrabodies are intracellularly expressed, recombinant anti-
body fragments that provide a powerful therapeutic tool well
suited to treatment of protein misfolding neurodegenerative dis-
eases. Intrabodies recognizing different epitopes of the same pro-
tein can have vastly different effects (Khoshnan et al., 2002), and
they are capable of distinguishing between highly homologous
proteins and even different conformations of the same protein
(Zhou et al., 2004; Emadi et al., 2007). Intrabodies may also be
used to ectopically target proteins to particular cellular compart-
ments using localization sequences (Lecerf et al., 2001; Paganetti
et al., 2005).
A number of anti-Htt iAbs with therapeutic potential have
been generated and characterized. C4, an iAb that recognizes the
N terminus of Htt, reduces aggregation and toxicity in cell cul-
ture, brain slice, and Drosophila HD models (Murphy and
Messer, 2004;Wolfgang et al., 2005;McLear et al., 2008). This iAb
increases turnover of both wild-type (wt) and mutant HDx-1
(mHDx-1) in 293 cells (Miller et al., 2005). MW7 and Happ1,
iAbs recognizing the polyP and P-rich domains of Htt, respec-
tively, reduce mHDx-1 aggregation and toxicity in cell culture,
brain slice, and Drosophilamodels of HD, and increase turnover
of mutant but not wtHDx-1 (Khoshnan et al., 2002; Southwell et
al., 2008). VL12.3, an iAb that recognizes the N terminus of Htt,
potently reduces mHDx-1-induced toxicity in cell culture and
Received Aug. 31, 2009; accepted Sept. 22, 2009.
This work was funded by the Hereditary Disease Foundation, the CHDI Foundation, and the National Institute of
Neurological Disorders and Stroke (RO1 NS055298). We thank Ali Khoshnan for the mHtt lentiviral genome and for
much advice and guidance, David Colby and K. Dane Wittrup for VL12.3, David Anderson for 293-GPG cells, David
Baltimore for lentiviral production plasmids, Elio Vanin and Martha Bohn at Northwestern University for the AAV2
genomeplasmidwithmodified CBApromoter, theUniversity of Pennsylvania Viral Vector Core for the AAV1 rep/cap
plasmid, Beverly Davidson and theUniversity of IowaViral Vector Core for AAV1-GFP of known titer and for protocols
and technical support for AAV production and purification, Jeffrey Cantle andWilliamYang for BACHDmice,Michael
Hayden for YAC128 mice, and Wally Bugg for discussion and support.
Correspondence should be addressed to Paul H. Patterson, Division of Biology, California Institute of Technology,
216-76, Pasadena, CA 91125. E-mail: php@caltech.edu.
DOI:10.1523/JNEUROSCI.4286-09.2009
Copyright © 2009 Society for Neuroscience 0270-6474/09/2913589-14$15.00/0
The Journal of Neuroscience, October 28, 2009 • 29(43):13589–13602 • 13589
brain slice HDmodels (Colby et al., 2004; Southwell et al., 2008).
However, this iAb increases nuclear Htt (Southwell et al., 2008).
EM48, an iAb recognizing an epitope C-terminal to the PRR
of Htt, preferentially binds mHtt and increases turnover of
mHDx-1 in a cell culture model of HD. Adenoviral delivery of
EM48 to the brains of R6/2 and N171-82Q HD model mice im-
proves some aspects of neuropathology as well as motor perfor-
mance in N171-82Q mice (Wang et al., 2008). This adenoviral
delivery strategy is limited to the study of short life span HD
models because of the transient transgene expression of the ad-
enoviral vector. While both vectors can infect neurons (depend-
ing on the serotype), the adeno-associated virus (AAV) vector is
preferable due to its more stable expression.
Due to the clear mechanistic differences of VL12.3 and Happ1
as potential therapeutics and the lack of a single, ideal mouse HD
model, we tested both iAbs for therapeutic efficacy in a lentiviral
model and four transgenic HD mouse lines using intrastriatal
AAV delivery.
Materials andMethods
Lentivirus production and purification. Ten 15 cm plates of 80% con-
fluent 293 GPG cells (Ory et al., 1996) were triple transfected by calcium
phosphate with 20 g of pFugW lentiviral genome encoding either
mHDx-1Q103-GFP or GFP (A. Khoshnan, Caltech, Pasadena, CA), 15
g of 8.9, and 10 g of VSV-G plasmids (Naldini et al., 1996). Sixteen
hours post-transfection, medium was removed and replaced with me-
dium supplemented with 2% FBS. Medium containing lentivirus was
collected at 48 and 72 h post-transfection, filtered at 0.45 m, and cen-
trifuged for 90 min at 25,000 rpm at 4°C to pellet lentivirus. Pellets were
then dissolved overnight at 4°C in sterile PBS. Viral solutions were buffer
exchanged into sterile saline (0.9% NaCl) and concentrated using Ami-
con ultra 4 ml tubes [MW cutoff (MWCO) 100,000] (Millipore) until a
final volume of 150–250l was reached, aliquotted, and stored at80°C
until use. Viral biological titer was determined by infection of HEK 293
cells with a dilution series and counting colonies of GFP-positive cells
(Tiscornia et al., 2006). Biological titer was used rather than quantitation
of p24 to ascertain the number of infectious particles. Before injection, all
lentiviruses were adjusted to a titer of 5 108 transducing units/ml.
AAVproduction and purification. Fifty 15 cmplates of80%confluent
HEK 293 cells were triple transfected by calcium phosphate with 12.5g
of AAV serotype 2 genome (Stratagene) with a modified chicken -actin
promoter plus CMV promoter enhancer regions (CBA) (Northwestern
University Viral Vector Core) encoding GFP, VL12.3, or Happ1, 25g of
pHelper (Stratagene), and 37.5g of AAV serotype 1 rep/cap (University
of Pennsylvania Viral Vector Core) plasmids per plate. Medium was
replaced 16 h post-transfection. At 48 h post-transfection, medium was
removed and cells were dislodged by pipetting, collected by centrifuga-
tion, and washed with and resuspended in 10 mM Tris buffer. Cells were
lysed by two rounds of freeze/thaw with vortexing and treated with
DNase I for 30 min. at 37°C. The viral fraction was then isolated by
ultracentrifucation at 40,000 rpm for 2 h at 4°C in an optiprep gradient
(15–60%) (Sigma). The fraction containing the virus (40–60% inter-
face) was collected by syringe, diluted 1:5 in 20 mM Tris buffer, pH 8.0,
and further purified by Mustang-Q membrane ion exchange (Acrodisc,
Pall). Virus was eluted in 500 l of 20 mM Tris buffer, pH 8.0, with 400
mM NaCl and stored at80°C in 50 l aliquots. Before use each aliquot
was dialyzed in a slide-a-lyzer mini dialysis unit (MWCO 7000, Pierce)
for 1 h at 4°C in 1 L of sterile saline with gentle stirring. Viral titer was
determined by qPCR of a dilution series using primers that recognize the
inverted terminal repeats and comparison to AAV of a known titer ob-
tained from theUniversity of IowaViral VectorCore. Before injection, all
AAVs were adjusted with sterile saline to a titer of 1  1013 viral
particles/ml.
Animals. Mice were obtained from the Jackson Laboratory [C57BL/6
and BACHD (through the laboratory of W. Yang, University of Califor-
nia, Los Angeles, Los Angeles, CA)] or bred in the Caltech facility from
breeding pairs obtained from the Jackson Laboratory (R6/2, N171-82Q,
and YAC128). Due to the infertility of the R6/2 line, ovarian transplant
hemizygote females andwtmaleswere used.Wild-type females andhem-
izygote males were used for mating in the N171-82Q and YAC128 lines.
Genotyping PCR was performed as specified on the Jackson Laboratory
website. Due to the high demand for the relatively new BACHD model,
an all-male cohort with wt littermates could not be obtained. However,
this model is on the same genetic background as the YAC128 model, so
wt mice from the BACHD line are expected to perform similarly to wt
mice from the YAC128 line. Experimental data were analyzed indepen-
dently for each gender and combined only if there was no significant
difference betweenmale and femalemice.Micewere housed in ventilated
cages and all surgical and experimental procedures were performed ac-
cording to Institute Animal Care and Use Committee specifications.
Surgeries. Adult mice were anesthetized with 500 mg/kg ketamine and
100 mg/kg xylazine and placed in a stereotaxic frame. After shaving and
disinfection of the scalp, an incision was made along the midline. A
dental drill was used to make a burr hole at 0.75 mm anterior and 2 mm
lateral to bregma. Injections were done at a depth of 3.5 mm from the
dura using a 5 l Hamilton syringe and removable 30-gauge needle with
a 20° bevel tip attached to an ultra micropump III and micro4 controller
(World Precision Instruments). After injection, the needle was left in
place for 5 min and withdrawn slowly. Incisions were closed using vet
bond glue (3M) andmice were allowed to recover on a heating pad.Mice
were checked for general health daily for 3 d following surgery.
For the lentiviral model, four-week-old C57BL/6 mice were injected
unilaterally in the striatum on alternating sides with 4 l of mHDx-1 or
GFP lentivirus plus 1 l of GFP, VL12.3, or Happ1 AAV at a rate of 0.5
l/min (10 mice per group). Four-week-old male N171-82Q and wt
littermates were injected bilaterally in the striatum with 1 l of GFP or
Happ1 AAV followed by 4 l of sterile saline at a rate of 0.5 l/min (10
mice per group). The needle was loaded first with saline and then with
virus so that saline is injected after the virus and serves to push virus into
the brain, increasing spread. Two-month-old male YAC128 and wt lit-
termates were injected bilaterally in the striatum with 1 l of GFP,
VL12.3, or Happ1 AAV followed by 4 l of sterile saline at a rate of 0.5
l/min (10 mice per group). Two-month-old male and female BACHD
mice were injected bilaterally in the striatum with 1 l of either GFP or
Happ1 AAV followed by 4 l of sterile saline at a rate of 0.5 l/min (five
females and four males per group).
Postnatal day 3 male R6/2 and wt littermates were anesthetized by
hypothermia by submersion in ice water inside a latex glove for 5 min.
Pupswere then placed on an ice packwith their heads stabilized in a putty
mold for the duration of the surgery. After disinfecting the scalp, a 5 l
Hamilton syringe with a removable 33-gauge needle with a 20° bevel tip
was pushed through the skin and skull at approximately the center of
each forebrain hemisphere to a depth of 2.5 mm. Bilateral injections of 1
l of GFP, VL12.3, or Happ1 AAV at a rate of 0.1l/min were performed
using an ultra micropump III and micro4 controller. The needle was left
in place for an additional 5min andwithdrawn slowly. Pupswere allowed
to recover on a 37°Cwater circulating heating pad, and a small amount of
the dam’s urine was rubbed on their rump to prevent subsequent canni-
balism. Pups were checked for the presence of a milk spot 2 h after
surgery and for general health daily for three subsequent days. After
weaning, genotyping was performed to determine how many mice from
each of the six groups had been injected until aminimumof 20 per group
was reached. Ten mice per group were killed for histology at 10 weeks of
age, while the remaining mice were studied until the point of mortality.
Behavioral assays. All behavioral experiments were conducted during
the light cycle by a researcher blind to genotype and treatment group.
Repeated tests were conducted at approximately the same time of day.
Single-time-point behaviors were compared using ANOVA. Repeated
behavior tests were compared using repeated-measures ANOVA for lines
in which all animals were killed at the same age (YAC128 and BACHD)
and two-wayANOVAat individual timepoints for lines inwhich animals
were tested until a disease-related endpoint was reached and therefore
not killed at the same age (R6/2 andN171-82Q). Bonferroni post hoc tests
were used to determine significance.
Rotarod. The latency to fall from an accelerating rotarod (Ugo Basile)
beginning at 5 rpm and accelerating to 40 rpm over 240 s was scored.
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Mice were allowed to stay on the rotarod for a maximum of 300 s. Mice
were trained before the initial test for two consecutive days for R6/2,
N171-82Q, and YAC128 lines and for three consecutive days for the
BACHD line. Two trials were performed per training day with a 10 min
intertrial interval (ITI). On testing days, two trials were performed sep-
arated by a 10 min ITI. Only the second trial was scored.
Beam crossing. The time to cross the center 80 cm of a 1 m beam was
scored. Three square beams of different widths were used (28, 12, and 6
mm). The beams were mounted atop poles (50 cm above the tabletop)
with a bright light at the starting end and a dark box containing the
animal’s home cage nestmaterial at the far end. Anylonhammock 7.5 cm
above the tabletop was used to prevent injury to mice falling from the
beam. Mice were placed at the end of the beam with the bright light and
the time fromwhen the entire body of themouse entered to the time that
the nose of the mouse exited the center 80 cm was measured using an
electronic infrared interrupt sensor. The 80 cm section is used because
the mice sometimes hesitate before starting and before entering the dark
box.Micewere trained before the initial test for three consecutive days on
all beams with a 10 min ITI between beams. During training, mice were
encouraged to keep moving across the beam by nudging and tail pinch-
ing. Training trials were repeated until each animal crossed the beam
three times without stopping or turning around. On testing days, three
trials were performed per mouse for each beam with a 10 min ITI be-
tween beams. Trials in which the animal took longer than 60 s to cross or
fell off the beamwere scored as 60 s. Trials inwhich the animal stopped or
turned around were repeated. The average of the trials was scored.
Climbing. Mice were placed at the bottom end of a closed-top wire
mesh cylinder (10  15 cm) on the tabletop and recorded with a video
camera for 5 min. The time from when a mouse’s fourth foot left the
tabletop to the time when the first foot was replaced on the tabletop was
scored as time spent climbing. The sum of climbing time for the 5 min
trial was compared.
Clasping. Animals were suspended by the tail 30 cm above the
tabletop for 1 min and recorded with a video camera. No clasping was
scored as 0, forelimb clasping was scored as 1, and hindlimb clasping
was scored as 2.
Amphetamine-induced rotation. Mice were injected intraperitoneally
with 10 mg/kg amphetamine in sterile saline and placed in a 50 50 cm
open white Plexiglas box with 16 cm sides. Activity was recorded for 30
min beginning 5 min after amphetamine injection by a ceiling-mounted
video camera. The number of ipsilateral rotations was counted. Only
rotations with a diameter similar to the animal’s body length or smaller
(as opposed to large circles around the edge of the box) were scored.
Open field, novel object, novel object location, and novel object preference.
Mice were placed in the lower left corner of a 50  50 cm open white
Plexiglas box with 16 cm sides in a roombrightly lit by fluorescent ceiling
lights. Open field activity was recorded for 10 min by a ceiling-mounted
video camera. Center entries and time spent in the center were scored.
Mice were then removed from the box for a 5 min ITI and two different
novel objects were placed in the upper two corners of the box, far enough
from the sides so as to not impedemovement around the outer edge (7
cm). Mice were reintroduced to the box in the lower left corner and
recorded for 5 min, during which the number of investigations of the
novel objects was scored. Episodes involving the mouse in close proxim-
ity to the objects but not facing or sniffing them were not considered
investigations. Circling or rearing on the objects with continued sniffing
was considered a single investigation, while episodes in which the mouse
sniffed the object, turned away, or reared against the wall and subse-
quently turned back to sniff the object again were considered separate
investigations.Micewere then removed from the box for a 5min ITI, and
the object at the top right corner of the box was moved to the lower right
corner of the box. Mice were reintroduced to the box and recorded for 5
min, and the number of investigations of the objects was scored. For
novel object location testing, the percentage of the investigations, or nose
pokes, to the target object (the one in the new location) was computed.
For novel object preference testing, the experiment was repeated on the
subsequent day with the exception that rather than repositioning the
object in the top right corner, it was replaced by a different, unfamiliar
object in the same location. The percentage of the investigations of the
target object (the unfamiliar one) was computed.
Histology. Brain tissue was fixed by transcardiac perfusion of 4% PFA
in PBS. Brains were postfixed in ice-cold 4% PFA in PBS for 45 min and
then placed in 30% sucrose at 4°C overnight until they sunk. Brains were
then embedded in optimal cutting temperature embeddingmedium and
cut in 16 m slide-mounted coronal sections. Sections were stored at
20°C until immunohistochemistry (IHC). For IHC, sections were
blocked for 30 min at room temperature in 3% BSA, 10% normal goat
serum, 0.1% Triton X-100, and 0.02% sodium azide in PBS. Antibodies
were diluted in the blocking solution. Primary antibodies were incubated
on sections overnight or for 48 h (anti-HA) at 4°C. Secondary antibodies
were incubated on sections for 2 h at room temperature. Primary anti-
bodies used include rabbit anti-DARPP-32 (1:500, Millipore Bioscience
ResearchReagents),mouse anti-HttMW8 (Ko et al., 2001), mouse anti-Htt
EM48 (1:1000,Millipore Bioscience ResearchReagents), rabbit anti-GFP
(1:400, Invitrogen),mouse anti-NeuN (1:500,DAKO), rabbit anti-GFAP
(1:500 Millipore Bioscience Research Reagents), and mouse anti-HA (1:
200, Covance). Secondary antibodies used include Alexa-fluor 350
(blue)-, 488 (green)-, and 568 (red)-labeled goat anti-mouse or anti-
rabbit (1:250, Invitrogen). Topro-3 iodide nuclear stain (Invitrogen) was
incubated at 1:5000 in PBS for 5 min at RT after secondary antibody.
Animals with50% of the striatal area transduced at 0.75 mm anterior
to bregma were eliminated from all behavioral and histological analyses.
Quantification of IHC was compared using two-way ANOVA and Bon-
ferroni post hoc tests for significance.
Lentiviral HD model. Three sections per mouse selected from the an-
terior region of the forebrain (1.7–2 mm anterior to bregma), the injec-
tion site (0.75 mm anterior to bregma), and the posterior region of the
forebrain (0.8–1 mm posterior to bregma) were stained for GFP (green)
and HA (iAb, red) to determine the extent of viral transgene spread. In
the case of the iAb-treated groups, these sections were also used to deter-
mine the similarity of spread and cotransduction efficiency of the
mHDx-1 lentivirus and iAbAAV. Three sections permouse selected near
the injection site were stained for Htt inclusions (MW8, green),
DARPP-32 (red), and all nuclei (blue). MW8 is an Ab that recognizes a
unique epitope in the C terminus of HDx-1 and preferentially binds
aggregated Htt (Ko et al., 2001). This Ab was used to quantify inclusions.
Striatal Htt inclusions were quantified by counting green foci larger than
2 pixels at 40magnification for each section. Striatal DARPP-32 stain-
ing was assessed both for the area of the lesion and for the intensity of
staining within the lesion. For lesion area, the ratio of the area of total
DARPP-32 loss to the area of striatal lentiviral transgene spread was
calculated. For staining intensity, the ratio of DARPP-32 (red fluores-
cence) staining in the transduced area of the injected striatum to
DARPP-32 staining in the same area of the contralateral, uninjected
striatumwas calculated. ImageJ was used for all three quantifications. To
further characterize lesions, two sections per mouse were stained for
DARPP-32 (red), GFAP (green), and NeuN (blue) or all nuclei (topro-3
iodide, blue).
R6/2 HD model. Three sections per mouse selected from the anterior
region of the forebrain, the injection site (0.75 mm anterior to
bregma), and the posterior region of the forebrain from both the group
killed at 10weeks of age and the groupused to assess survival were stained
for GFP (green) and HA (red) to determine the extent of viral transgene
spread. Three sections permouse at approximately bregma 0.0mm from
the group killed at 10 weeks of age were stained forHtt inclusions (MW8,
green), DARPP-32 (red), and all nuclei (topro-3-iodide, blue). Small Htt
aggregates were quantified by counting green foci 2–8 pixels in size
within a 250 m2 area of the transduced striatum. Intranuclear inclu-
sions were quantified by counting green foci 9–15 pixels in size that
colocalized with topro-3-iodide staining. DARPP-32 was quantified by
mean red fluorescence intensity of the entire striatal area of both hemi-
spheres. Ventricle area was also measured for both hemispheres of these
sections by tracing its outline (area computed in arbitrary units). ImageJ
was used for all three of these measures.
N171-82Q HD model. Three sections per mouse selected from the
anterior region of the forebrain, the injection site (0.75 mm anterior to
bregma), and the posterior region of the forebrain were stained for GFP
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(green) and HA (red) to determine the extent of viral transgene spread.
Neuropathological markers were not assessed for these animals as they
were used to assess survival and were therefore not killed at the same age
but at the same disease stage.
YAC128 and BACHD HD models. Three sections per mouse selected
from the anterior region of the forebrain, the injection site (0.75 mm
anterior to bregma), and the posterior region of the forebrain were
stained for GFP (green) and HA (red) to determine the extent of viral
transgene spread. Three sections permouse at approximately bregma 0.0
mm were stained for Htt inclusions (EM48, green), DARPP-32 (red),
and all nuclei (blue). DARPP-32 was quantified by mean red fluores-
cence intensity of the entire striatal area of both hemispheres. Ventricle
size was also measured for both hemispheres of these sections. ImageJ
was used for these measures.
Survival.When animals became obviously ill, they were assessed twice
daily for the loss of righting reflex. If animals failed to right themselves
immediately after being laid on their side in the home cage, they were
killed.
Results
Widespread striatal transduction is achieved with the
lentiviral vector in adult mice and with the AAV vector in
adult and neonatal mice
In the lentiviral model, adult wt mice were unilaterally injected
with amixture ofmHDx-1 orGFP lentivirus, plusGFP-, VL12.3-,
or Happ1-AAV. Mice were killed 6 weeks later and coronal sec-
tions throughout the striatumwere stained formHDx-1 and iAb.
Similar striatal spread is seen with both lentivirus and AAV (Fig.
S1A, available at www.jneurosci.org as supplemental material).
Colocalization of mHDx-1 and iAb in confocal images shows
that these viruses cotransduce cells (Fig. S1B, available at www.
jneurosci.org as supplemental material). There are a larger num-
ber of iAb-positive cells than mHDx-1-positive cells, suggesting
greater transduction efficiency for AAV2/1. Adult injections of
AAV2/1 were also used bilaterally in N171-82Q, YAC128, and
BACHDHD transgenic mice. Striatal iAb spread in these mice is
similar to that seen in the lentiviral model (data not shown). The
R6/2 model has an accelerated time frame that includes Htt in-
clusions at birth and onset of behavioral symptoms at3 weeks
of age (Mangiarini et al., 1996; Stack et al., 2005). Because of this
and the 3 week delay before AAV delivered transgene expression
reaches its peak (Tenenbaum et al., 2004), postnatal day 3, rather
than adult, injections were used in this line. Striatal spread equiv-
alent to or better than that seen with adult injections is appar-
ent (Fig. S1C, available at www.jneurosci.org as supplemental
material).
Happ1 treatment improves rotarod performance in four
transgenic HD models
The ability to stay on a rotating rod is often used as a test of
sensory-motor ability. Mice were assessed for accelerating ro-
tarod performance as follows: weekly from 4 weeks of age until
death in R6/2 and wt littermates (Fig. 1A), every 2 weeks from 6
weeks of age until death in N171-82Q and wt littermates (Fig.
1B), monthly from 3 until 7 months of age in YAC128 and wt
littermates (Fig. 1C,D), andmonthly from3until 6months of age
in BACHD mice (Fig. 1E). Compared with wt littermates, R6/2
mice display a deficit in rotarod performance from5weeks of age.
Compared with GFP treatment, Happ1 treatment ameliorates
this deficit between 9 and 12 weeks of age (Fig. 1A). In contrast,
compared with GFP treatment, VL12.3 treatment reduces latency
to fall in R6/2 mice between 10 and 12 weeks of age. Although
rotarod performance is also impaired below GFP controls at 13
weeks of age, statistics cannot be performed, as only one VL12.3-
treatedmutant remained alive at this time point. Compared with
wt littermates, N171-82Q mice display a motor deficit on the
rotarod from 20 weeks of age. From 22 weeks of age performance
is significantly improved by Happ1 treatment (Fig. 1B). Happ1-
treated mutants do not differ from wt animals in their perfor-
mance until 40 weeks of age.
Happ1 treatment also improves rotarod performance in 3-,
4-, and 7-month-old YAC128 mice (Fig. 1C,D). The lack of sig-
nificant difference at 5 and 6 months of age appears to be related
to an improvement in the performance of GFP-treated animals
rather than a decline in the performance of Happ1-treated mice.
YAC128 mice display a learning deficit that includes impaired
learning of the rotarod task from 2months of age (Van Raamsdonk
et al., 2005). As rotarod training was performed at 3 months of
age with the same number of training trials for all mice, the dif-
ference in performance between young GFP- and Happ1-treated
mice could be the result of enhanced learning of the task by
Happ1 treatment. By 7 months of age, the performance of GFP-
treated YAC128 mice begins to decline, presumably as a result of
declining motor ability. Happ1 treatment also ameliorates the
motor deficit in the BACHD line. Compared with GFP treat-
ment, Happ1 treatment increases the latency to fall from the
rotarod in 5- and 6-month-old BACHDmice (Fig. 1E). In sum-
mary, Happ1 attenuates the loss of motor function in the rotarod
test induced by mHtt in four HD mouse models.
Happ1 treatment improves beam-crossing performance in
four transgenic HD models
Similar to the rotarod, beam crossing is an objective assay for
balance and motor function. Mice were assessed for beam-
crossing performance as follows: weekly from 4weeks of age until
death in R6/2 andwt littermates (Fig. 2A; Fig. S2A–C, available at
www.jneurosci.org as supplemental material), every 2 weeks
from 6 weeks of age until death in N171-82Q and wt littermates
(Fig. 2B; Fig. S2D–F, available at www.jneurosci.org as supple-
mental material), monthly from 3 until 7 months of age in
YAC128 andwt littermates (Fig. 2C; Fig. S2G–I, available at www.
jneurosci.org as supplemental material), and monthly from 3
until 6 months of age in BACHD mice (Fig. 2D; Fig. S2 J–L,
available at www.jneurosci.org as supplemental material). Three
widths of square beam were used: 28, 12, and 6 mm. The data for
the former two widths are shown in Fig. S2, available at www.
jneurosci.org as supplemental material. Compared with wt litter-
mates, R6/2 mice display increased time to cross the beams from
10, 7, and 5weeks, respectively. Being the easiest to traverse, there
are no significant effects of iAb treatment on time to cross the 28
mm beam. However, compared with GFP treatment, Happ1
treatment does reduce the time to cross the 12 mm beam in 10-
and 11-week-old R6/2 mice, and the 6 mm beam between 9 and
11 weeks of age. Conversely, compared with what was seen for
GFP-treated littermates, VL12.3 treatment increases the time to
cross the 12 mm beam at 11 and 12 weeks of age and the 6 mm
beam at 9 and 10 weeks of age (Fig. S2A–C, available at www.
jneurosci.org as supplemental material).
N171-82Q mice display increased time to cross the three
beams at 22, 16, and 12 weeks, respectively (Fig. S2D–F, available
at www.jneurosci.org as supplemental material). Happ1 treat-
ment significantly reduces time to cross the 28mmbeam from 22
weeks of age on, the 12mmbeam inmutants 16, 18, and 24weeks
old and older, and the 6 mm beam in mutants 18, 20, and 26
weeks old and older. Happ1-treated mutants only show a deficit
compared with wt mice in time to cross the 12 mm beam at 30
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and 40 weeks of age and the 6 mm beam at 28, 30, 38, and 40
weeks of age.
Compared with wt littermates, YAC128 mice display im-
paired beam-crossing performance at 7 months of age for the
28 mm beam and 3 and 4 months of age for the 12 and 6 mm
beams (Fig. S2G–I, available at www.jneurosci.org as supple-
mental material). Compared with GFP treatment, Happ1
treatment reduces the time to cross the 28 mm beam in
7-month-old YAC128 mice and the 12 and 6 mm beams at 3
and 4 months (Fig. 2C; Fig. S2G–I, available at www.jneurosci.
org as supplemental material). As in the rotarod test, the per-
formance of the GFP-treated YAC128 mice appears to improve
over the earliest time points, consistentwith themotor task learn-
ing deficit reported for these mice (Van Raamsdonk et al., 2005).
The Happ1-induced improvement at the early time points
suggests an improved learning of the task. In contrast, VL12.3
treatment appears to exacerbate this early learning deficit in
3-month-old mice. Happ1 treatment of BACHD mice reduces
the time to cross the beams at 5 and 6 months for the 28 mm
beam, at 4 and 6months for the 12mmbeam, and at 6months for
the 6 mm beam (Fig. 2D; Fig. S2 J–L, available at www.jneurosci.
org as supplemental material). In summary, Happ1 attenuates
the loss of motor function in the beam-
crossing test induced by mHtt in four HD
mouse models.
Happ1 treatment improves climbing
performance in YAC128 and
BACHD mice
Climbing in a single episode is a useful
measure of motor ability that is not com-
plicated by potential learning deficits, and
is thus well suited to the YAC128 model.
Climbing time was assessed in 7-month-
old YAC128 and wt littermates (Fig. 3A)
and in 6-month-old BACHD mice (Fig.
3B). Mice were placed at the bottom of a
closed-top wire mesh cylinder and ob-
served for 5 min. Time spent climbing
with all four feet off of the tabletop was
scored. Compared with wt littermates,
GFP- and VL12.3-treated YAC128 mice
investigate the wire mesh and rear on two
or three legs frequently, but climbing time
is reduced (Movie S3). Happ1 treatment
increases climbing time in these mice to a
level not significantly different from wt
mice (Fig. 3A). ComparedwithGFP treat-
ment, Happ1 treatment also increases
climbing time in BACHD mice (Fig. 3B).
Thus, Happ1 attenuates the loss of motor
function in the climbing test induced by
mHtt in two HD mouse models.
Happ1 treatment ameliorates clasping
in N171-82Q mice
Since clasping is seen in severalneurodegen-
erative disease models, it is often used as a
test for potential therapeutics. The pathol-
ogy underlying clasping is not understood,
however. Twenty-week-old N171-82Q and
wt littermates were assayed for clasping.
Clasping was not assessed in YAC128 or
BACHD mice, as this behavior has not been reported in these
lines. Mice were suspended by the tail and observed for 1 min.
Mice with normal limb extension were given a score of 0. Fore-
limb clasping was scored as 1, and hindlimb clasping was scored
as 2 (Fig. 3C). Wild-type mice do not exhibit clasping. All GFP-
treatedN171-82Qmice exhibit clasping, with approximately half
displaying forelimb-only clasping and half displaying hindlimb
clasping. The majority of Happ1-treated mutants display
forelimb-only clasping, while a few display hindlimb clasping or
no clasping (Fig. S4A, available at www.jneurosci.org as supple-
mental material). Thus, Happ1 attenuates the abnormal motor
behavior induced by mHtt in this HD mouse model.
Treatment with VL12.3 or Happ1 prevents abnormal
amphetamine-induced rotation behavior in the lentiviral
HDmodel
Four-week-old C57BL/6 mice were injected unilaterally with
mHDx-1 or GFP lentivirus plus GFP-, VL12.3-, or Happ1-AAV.
Six weeks after surgery, animals were injected with 10 mg/kg
amphetamine, intraperitoneal. After 5 min, animals were placed
in an open field for 30min and ipsilateral rotations counted (Fig.
3D). Age-matched, uninjected mice were also tested as a control
Figure1. Happ1 treatment improves rotarod performance in four HDmousemodels. Mice were tested on an accelerating
rotarod for a maximum of 300 s. A, Male R6/2 and wt littermates were tested weekly: Happ1 treatment significantly
improves performance during weeks 9 –12, while VL12.3 treatment degrades performance during weeks 10 –12. B, Male
N171-82Q and wt littermates were tested every other week. Happ1 treatment improves performance to a level not
different from wt animals from 22 weeks until 38 weeks. C, Male YAC128 and wt littermates were tested monthly and
Happ1 (but not VL12.3) treatment significantly improves performance at months 3, 4, and 7. D, YAC128 rotarod perfor-
mance only for GFP- and Happ1-treatedmutant groups is shown for simplicity. E, Male and female BACHDmice were tested
monthly: Happ1 treatment significantly improves performance at months 5 and 6. Asterisks indicate difference between
GFP- and iAb-treated mutants. *p 0.05, **p 0.01, ***p 0.001.
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for surgery effects. Naive mice were ran-
domly assigned to right turn or left turn
groups for scoring ipsilateral turns.
Compared with what was seen for naive
mice, injection of GFP lentivirus along
with any of the AAVs does not signifi-
cantly increase the number of ipsilateral
rotations. In contrast, animals injected
with mHDx-1 lentivirus plus GFP-AAV
display a major increase in ipsilateral ro-
tations. Coinjection of VL12.3- or Happ1-
AAV strongly reduces the number of
ipsilateral rotations in mHDx-1 lentivirus-
injected animals to levels not significantly
different from GFP lentivirus-injected or
naive animals. Thus, the iAbs attenuate the
dopamine-driven motor abnormality in-
duced by mHtt in the lentiviral HD mouse
model.
Happ1 treatment normalizes open field
behavior in full-length Htt transgenic
models of HD
Although increased anxiety has not previ-
ously been reported for YAC128 and
BACHD mice, we observed that some of
the mice exhibit progressive, researcher-
induced anxiety. As a result, 7-month-old
YAC128 and wt littermates and 6-month-
old BACHD mice were assayed for anxiety during open field
exploration (Fig. 4). Compared with wt littermates, GFP-
treated YAC128mice display reduced entries into, and time spent
in, the center of the field, which suggests enhanced anxiety. In
contrast, Happ1 treatment increases center entries and time in
the center to levels not significantly different from wt mice (Fig.
4A,B). In the BACHDmice, there is a trend toward an increased
number of center entries as a result of Happ1 treatment, but it
does not reach significance (Fig. 4C). However, compared with
what was seen for GFP-treated BACHD mice, Happ1 treatment
significantly increases the time spent in the center of the open
field (Fig. 4D). Thus, Happ1 attenuates anxiety in two full-length
HD models.
Happ1 treatment improves learning in YAC128 mice
Due to the learning deficit reported for YAC128 mice (Van
Raamsdonk et al., 2005), and the indication from motor testing
that this deficitmay be ameliorated byHapp1 treatment, learning
was assayed in the full-length transgenic models. Although iAb
was delivered to the striatum, extensive viral spread also results in
cortical and hippocampal transgene expression (Fig. S1A,D,
available at www.jneurosci.org as supplemental material), which
could affect learning. The HD-like phenotype of these models
includes altered motor performance and motivation. Therefore,
learning was assayed using the novel object location and novel
object preference tests (Mumby et al., 2002, Mumby et al., 2007),
which do not require training or depend on the speed of swim-
ming or running, allowing the testing of learning with less influ-
ence of motor ability and motivation.
To assess hippocampal-dependent learning, 7-month-old
YAC128 and wt littermates and 6-month-old BACHDmice were
tested for preference for the novel location of a known object
(Fig. 5A) (Mumby et al., 2002).Onday 1,micewere habituated to
an open field. After a 5 min ITI they were reintroduced to the
same field now containing two novel objects in the upper corners
of the box located far enough from the sides to allow free move-
ment around the outer edge. Investigations of each object were
scored for 5 min (trial 1, T1). In trial 2 (T2) after another 5 min
ITI, they were reintroduced to the same field with the object
previously located in the upper right corner moved to the lower
right corner. Investigation of each object was scored for 5 min,
and the percentage of the investigations, or nose pokes, to the
target object (the one that was moved) was computed. A score of
50% represents no preference. As expected, wt mice of the
YAC128 line display no preference in T1 and a preference for the
target object in T2 (Fig. 5C). In contrast, GFP- and VL12.3-
treated YAC128 mice display no preference in either trial, indi-
cating impaired spatial learning. However, Happ1 treatment
restores significant spatial learning (Fig. 5C). BACHD mice in
both treatment groups show no preference for the target object,
indicating impaired spatial learning and no effect of iAb treat-
ment (Fig. 5E).
To assess cortical-dependent learning, mice were tested for
preference for a novel object (Fig. 5B) (Mumby et al., 2007). On
day 2, mice were rehabituated to the same field and T1 from day
1 was repeated. In T2 they were reintroduced to the field with the
object in the upper right corner replaced with a completely novel
object. Investigation of each object was scored for 5 min, and the
percentage of the investigations of the target object (the com-
pletely novel object) was computed. Wild-type mice of the
YAC128 line display no preference in T1 and trended toward a
preference for the target object in T2, although the difference is
not significant. There are no differences between the treatment
groups in wt mice, and when all wt groups are combined, the
preference for the target object reaches significance ( p  0.01)
(data not shown) indicating that the lack of significant preference
is related to small sample size. GFP- and VL12.3-treated YAC128
mice display no preference for the target object, indicating im-
Figure 2. Happ1 treatment improves beam-crossing performance in four HDmouse models. Time to cross the center 80 cm of
a square, 1-m-long, 6-mm-wide beam was measured. A, Male R6/2 and wt littermates were tested weekly: Happ1 treatment
improves performance during weeks 9–11, while VL12.3 treatment degrades performance at 9 and 10 weeks. B, Male N171-82Q
and wt littermates were tested every other week: Happ1 treatment improves performance at 18 weeks of age and older. C, Male
YAC128 andwt littermates were testedmonthly: Happ1 treatment improves performance at 3 and 4months.D, Male and female
BACHD mice were tested monthly: Happ1 treatment improves performance at 6 months. Asterisks indicate difference between
GFP- and iAb-treated mutants. *p 0.05, **p 0.01, ***p 0.001.
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paired cortical learning. In contrast, Happ1-treated YAC128
mice display a preference for the target object, indicating pre-
served cortical learning (Fig. 5D). In the BACHD line, GFP-
treated mice display no preference for the target object in T2
while Happ1-treated mice trended toward a preference for the
target object, although this does not reach significance (Fig. 5F).
In summary, Happ1 attenuates a cognitive deficit in a full-length
HD model.
Figure 3. Happ1 treatment improves climbing andprevents clasping inHD transgenicmice, and
VL12.3 or Happ1 treatment prevents the amphetamine-induced rotation phenotype caused by
mHDx-1 lentivirus.A,B,Micewereplacedat thebottomofaverticalwiremeshtubeandobservedfor
5min. The timewhenall four feetwereoff thegroundwasscoredas climbing time.A, Seven-month-
old GFP- and VL12.3-treated YAC128 mice have impaired climbing compared with wt mice. This is
rescued by Happ1 treatment. B, Happ1 treatment improves climbing time in 6-month-old BACHD
mice. C, Twenty-week-oldmale N171-82Q andwt littermateswere suspended by the tail, observed
for 1 min, and given a clasping score as follows: no clasping 0, forelimb clasping 1, hindlimb
clasping 2. D, Wild-type mice were injected unilaterally at 4 weeks of age with mHDx-1 or GFP
lentivirusplusGFP-,VL12.3-,orHapp1-AAV.At10weeksofagemicewereassayedforamphetamine-
induced rotation.Uninjected (naive)animalswere testedasanegative control.Animals injectedwith
mHDx-1 lentivirus and GFP-AAV exhibit many ipsilateral rotations in response to amphetamine.
VL12.3 or Happ1prevents this phenotype. *p 0.05, **p 0.01, ***p 0.001.
Figure 4. Happ1 treatment normalizes open field behavior in full-length transgenicmodels
of HD. Mice were observed for 10min during exploration of an open field. Anxiety was inferred
by scoring entries into, and time spent in, the center of the open field. A, C, There was a trend
toward increased center entries for bothmodels in response to Happ1 treatment, but it was not
significant. B, D, Happ1 treatment increases time spent in the center of the open field in
7-month-old YAC128 mice (B) and 6-month-old BACHDmice (D). *p 0.05, **p 0.01.
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In the lentiviral HDmodel, treatment
with VL12.3 or Happ1 ameliorates
neuron-specific mHDx-1 toxicity
DARPP-32 is a useful, specific marker of
the medium spiny neurons (MSNs) that
are lost in HD. Four-week-old C57BL/6
mice were injected unilaterally with
mHDx-1 or GFP lentivirus plus GFP-,
VL12.3-, or Happ1-AAV. Six weeks after
surgery, animals were perfused for histol-
ogy. Mice injected with mHDx-1 lentivi-
rus plus GFP-AAV display large areas of
strongly diminished DARPP-32 immu-
nostaining. Areas of DARPP-32 loss also
display loss of NeuN-positive cells, indi-
cating death of striatal neurons (Fig. 6A).
Topro-3 iodide nuclear staining does,
however, show the presence of cells within
lesioned areas, indicating hypersensitivity
of neurons to the toxicity of mHDx-1 len-
tivirus (Fig. 6B). Lesioned areas also dis-
play reactive gliosis, as evidenced by an
increase inGFAP staining (Fig. 6C). Coin-
jection of VL12.3- or Happ1-AAV with
mHDx-1 lentivirus reduces both the size
and intensity of DARPP-32 loss (Fig. 6D).
To quantify lesion size, the ratio of the
area of total DARPP-32 loss to the area of
lentivirus transduction was computed
(Fig. 6E). Animals injected with GFP len-
tivirus and any of the AAVs display very
small if any lesion areas. Injection of
mHDx-1 lentivirus with GFP-AAV causes
amajor lesion, which is reducedby coinjec-
tion of VL12.3- or Happ1-AAV to a level
not significantly different from animals
injected with GFP lentivirus plus any of
the AAVs.
To assess the severity of DARPP-32
staining loss within the lesion, the ratio of
DARPP-32 intensity within the trans-
duced striatum to DARPP-32 intensity in
the noninjected side was computed (Fig.
6F). Injection of mHDx-1 lentivirus plus
GFP-AAV causes a decrease inDARPP-32
intensity of the transduced striatum,
which is rescued by VL12.3- or Happ1-AAV to the level of ani-
mals injected with GFP lentivirus. Thus, both iAbs very effec-
tively prevent the mHtt-induced loss of MSNs in the lentiviral
model.
Treatment with VL12.3 or Happ1 reduces mHtt aggregation
in the lentiviral and R6/2 HD models
Coronal sections from mHDx-1 lentivirus-injected animals 6
weeks after surgery (Fig. S5A, available at www.jneurosci.org as
supplemental material) and 10-week-old R6/2 mice (Fig. S5B,
available at www.jneurosci.org as supplemental material) were
stained forHtt.Most of theHtt staining in bothmodels was in the
form of aggregates, although some diffuse staining in neurons is
seen (Fig. S5A, arrows in left panel, available at www.jneurosci.
org as supplemental material). VL12.3 or Happ1 treatment re-
duces aggregates and increases the level of diffuse Htt, both in
neuronal somas (arrows) and in the neuropil (Fig. S5A, available
at www.jneurosci.org as supplemental material). The larger areas
of bright staining in both the Happ1- and VL12.3-treated R6/2
brains appear to represent neuronal cytoplasm (Fig. S5B, avail-
able at www.jneurosci.org as supplemental material). Happ1-
treated brains appear to display lower overall levels of Htt
staining in bothHDmodels, although this was not quantified. To
quantify aggregation in the lentiviral model, three sections per
animal were stained with MW8, an anti-Htt antibody that
recognizes the C terminus of HDx-1 and preferentially labels
aggregated Htt in R6/2 mouse brains (Ko et al., 2001). Striatal
MW8-positive foci were counted and normalized to the area of
HDx-1 transduction (Fig. 7A). Treatment with VL12.3 or Happ1
dramatically reducesmHDx-1 aggregates. To quantify small neu-
ropil aggregates in the R6/2model, three sections per animalwere
stained with MW8 and topro-3 iodide nuclear marker. MW8-
positive foci of 2–8 pixels in size that do not colocalize with
topro-3 iodide in a 250m2 area of the transduced striatumwere
Figure 5. Happ1 treatment ameliorates the learning deficit of YAC128 mice. A, To assay for preference of a known object in a
novel location, mice were habituated to an open field for 10min. After a 5min ITI, they were exposed for 5min to novel objects in
the upper corners of the open field (T1). Investigation of the novel objects was scored. After another 5 min ITI, the mice were
reintroduced to the same field with the object previously in the upper right corner moved to the lower right corner (T2) for 5 min.
The percentage of the investigations of the target object (the one in the new location) was scored. A score of 50%would indicate
no preference. B, On the next day mice were tested for preference for a novel object. Mice were rehabituated to the open field for
10min. After a 5min ITI, theywere exposed for 5min to two objects in the upper corners of the open field (T1). Investigation of the
objects was scored. After another 5 min ITI the mice were reintroduced to the same field with the object in the upper right corner
replaced with a completely novel object in the same location. The percentage of the investigations of the target object (the
completely novel one)was scored. A score of 50%would indicate nopreference.C,D, Seven-month-old YAC128 andwt littermates
were tested. Wild-type mice display a preference for the novel object location (C) and a trend toward a preference for the novel
object (D). This does not reach significance, but when data from the three wt treatment groups are pooled, the preference is
significant ( p 0.01). GFP- and VL12.3-treated YAC128mice show no preference for either object in either paradigm, indicating
a learning deficit. Happ1 treatment improves this deficit. E, F, GFP- and Happ1-treated BACHDmice show no preference for either
object in either paradigm. There is a trend toward a preference for the novel object in Happ1-treated BACHDmice, but it does not
reach significance. *p 0.05, ***p 0.001.
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counted (Fig. 7B). Treatment with VL12.3 or Happ1 dramatically
reduces the number of these neuropil aggregates as well. To
quantify intranuclear inclusions,MW8-positive foci of 9–15 pix-
els in size that colocalize with topro-3 iodide staining were
counted (Fig. 7C). There is a trend toward a reduction of intranu-
clear inclusions in VL12.3-treated animals, and a significant re-
duction in Happ1-treated animals. Htt inclusions are not
observed in YAC128 or BACHD brains. This is not surprising as
inclusion formation has been reported to begin at 12 months of
age in YAC128 mice (Slow et al., 2005) and between 12 and 18
months of age in BACHD mice (Gray et al., 2008). In summary,
Happ1 strongly prevents the accumulation of mHtt aggregates in
the R6/2 and lentiviral models.
Happ1 treatment reduces ventricular enlargement in three
transgenic HD models
In R6/2 mice, ventricular enlargement is reported to begin at 3
weeks of age (Stack et al., 2005) and at 9 and 12 months in
YAC128mice (Slow et al., 2003). This pathology has not yet been
reported in BACHDmice. We assessed ventricle size in 10-week-
old R6/2 and wt littermates (Fig. 8A,B), in 7-month-old Yac128
and wt littermates (Fig. 8C), and in 6-month-old BACHD mice
Figure 6. mHDx-1 lentivirus causes neuron-specific toxicity in the striatum, which is reduced by VL12.3 or Happ1 treatment. Mice were injected unilaterally with mHDx-1 or GFP lentivirus plus
GFP-, VL12.3-, or Happ1-AAV. Areas with loss of DARPP-32 staining were analyzed. A, Areas of DARPP-32 loss (bottom) also show loss of NeuN-positive cells, indicating death of neurons in these
areas. B, Topro-3 iodide nuclear stain shows the presence of cells in lesioned areas, indicating that toxicity is neuron specific. C, Areas of DARPP-32 loss show increased GFAP staining, indicating
increased inflammation in lesioned areas. In A–C, the top shows GFP lentivirus and the bottom showsmHDx-1 lentivirus.D–F, Coinjection of either Happ1 or VL12.3 withmHDx-1 reduces the area
and intensity of DARPP-32 loss. D, Adjacent coronal sections stained either for mHDx-1 (green) or DARPP-32 (red). DARPP-32 loss is reduced in the presence of either intrabody. E, The ratio of the
area of total DARPP-32 loss to the transduced areawas compared to assess lesion size. Lesions are significantly smaller in the presence of either intrabody. Three sections permousewere analyzed.
F, The ratio of DARPP-32 staining fluorescence intensity in the transduced area of the striatum to DARPP-32 staining fluorescence intensity in the same size area of the uninjected striatum was
compared to assess the severity of the lesion. Lesions are less severe in the presence of iAb. Three sections per mouse were analyzed. *p 0.05, **p 0.01, Scale bars, 50m.
Southwell et al. • Intrabody Gene Therapy in Huntington’s Disease Mice J. Neurosci., October 28, 2009 • 29(43):13589–13602 • 13597
(Fig. 8D). Compared with wt littermates,
GFP- and VL12.3-treated R6/2 mice dis-
play very significant ventricular enlarge-
ment. Happ1 treatment reduces ventricle
size to a level not significantly different
from wt animals (Fig. 8A,B). Compared
with wt littermates, GFP- and VL12.3-
treated YAC128 mice display ventricu-
lar enlargement while Happ1 treatment
reduces ventricle size (Fig. 8C). In addi-
tion, Happ1-treated BACHD mice also
display smaller ventricles than GFP-
treated BACHD mice (Fig. 8D). As with
DARPP-32 neuropathology, Happ1 is
highly effective in preventing ventricu-
lar enlargement in three HD transgenic
models.
Happ1 treatment improves body weight
of N171-82Q mice
Body weight was assessed as follows:
weekly from 4 weeks of age until death in
R6/2 and wt littermates (Fig. 9A), every 2
weeks from 6 weeks of age until death in
N171-82Q and wt littermates (Fig. 9B),
monthly from 3 until 7 months of age in
YAC128 and wt littermates (Fig. 9C), and
monthly from 3 until 6 months of age in
BACHD mice (Fig. 9D). N171-82Q mice
weigh significantly less thanwt littermates
from 16 weeks of age onward. Happ1-
treated mutants, although still weighing
less than wt littermates, display increased
weight compared with GFP-treated mu-
tants from 22 weeks of age (Fig. 9; Fig.
S4B, available at www.jneurosci.org as
supplemental material). Compared with
wt littermates from 10 weeks of age, R6/2
mice display decreased body weight. In
contrast, YAC128 mice trend toward
greater body weight than wt littermates.
BACHDmales display greater body weight than females. There is
no effect of iAb treatment on this parameter in any of these three
models.
Happ1 treatment increases survival in N171-82Qmice while
VL12.3 treatment decreases survival in the R6/2 HDmodel
Life span was assessed in R6/2mice (Fig. 9E) andN171-82Qmice
(Fig. 9F). Once mice became visibly ill, they were assayed twice
daily for loss of the righting reflex.Mice who did not immediately
right themselves after being laid on their side were killed. Happ1
treatment has no effect on life span while VL12.3 treatment de-
creases survival time of R6/2 mice. However, Happ1 treatment
increases maximum life span of N171-82Q mice 33%, from 30
weeks of age inGFP-treatedmutants to 40weeks of age inHapp1-
treated mutants. Thus, Happ1 is effective in prolonging life span
in the less severe transgenic HD model.
Discussion
Viral vectors for gene therapy
AAV is a promising vector for gene therapy in humans.Wild-type
AAV is widespread in human populations, which reduces the
probability of host immune activation complications (Chirmule
et al., 1999; Peel and Klein, 2000). It is nonpathogenic in humans
and unable to replicate in the absence of a helper virus. A number
of clinical trials using AAV vectors to treat neurodegenerative
diseases have found no pathology related to the vector (McPhee
et al., 2006; Kaplitt et al., 2007;Marks et al., 2008). AAV can infect
both dividing and nondividing cells and is capable of generating
long-termtransgeneexpression,whichhasbeenmonitored forup to
six years innonhumanprimates (Klein et al., 2002; Bankiewicz et al.,
2006). Although wt AAV commonly integrates into genomic
DNA at specific sites, integration events for recombinant AAV
(rAAV), which lacks 96% of the viral genome, are rare, reducing
the probability of oncogenic complications (Schnepp et al.,
2003). The existence of120 different capsid proteins also con-
fers a wide range of tropisms allowing customization of rAAV
gene therapy vectors (Mueller and Flotte, 2008).
AAV2 is the most common serotype found in humans. As a
result, most early AAV gene therapy studies employ this serotype.
Although AAV2 is capable of long-term gene expression, this
serotype has low transduction efficiency, low viral spread in the
CNS, as well as an inability to transduce non-neuronal cells
(McCown et al., 1996; Bartlett et al., 1998; Klein et al., 1998;
Tenenbaum et al., 2000). Chimeric AAV2/1, consisting of the
Figure 7. VL12.3 or Happ1 decreases Htt aggregation in the lentiviral and R6/2 HD models. A–C, Three sections each of
6-weeks-postsurgery mHDx-1 lentivirus-injected (A) and 10-week-old (B, C) R6/2 brains were stained for Htt. A, The ratio of
striatal aggregates to transduced area is reduced by both intrabodies. B, The number of small Htt aggregates per 250 m2 is
reduced by both intrabodies. C, Happ1 treatment reduces the number of intranuclear inclusions per 250m2. *p 0.05, **p
0.01, ***p 0.001.
Figure 8. Happ1 treatment reduces ventricular enlargement in three HDmousemodels. A–D, Ventricle area wasmeasured at
approximately bregma 0.0 mm in three sections each from 10-week-old male R6/2 and wt littermates (A, B), 7-month-old male
YAC128 andwt littermates (C), and 6-month-oldmale and female BACHDmice (D). Both R6/2 and YAC128mice display increased
ventricle size compared with wt littermates. B–D, Happ1 treatment reduces ventricular enlargement in R6/2 mice (B), YAC128
mice (C), and BACHDmice (D). *p 0.05, **p 0.01, ***p 0.001.
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AAV2 genome and the AAV1 capsid protein, exhibits increased
spread and transduction efficiency, and the ability to transduce
glial and ependymal cells as well as neurons, while retaining the
long-term expression capabilities of AAV2 (Wang et al., 2003).
Chimeric AAV2/1 also has a decreased lag time between infection
and transgene expression (Auricchio et al., 2001).
Traditional AAV gene therapy vectors use the high-expressing
CMV promoter. However, gene expression from this promoter
in AAV infected cells in the CNS declines over time (McCown et
al., 1996; Klein et al., 1998; Tenenbaum et al., 2000). Use of CBA
stabilizes gene expression in AAV infected cells in the CNS (Klein
et al., 2002). Therefore, we used a chimeric AAV2/1 vector, con-
sisting of the AAV2 genome under the control of the CBA pro-
moter and the AAV1 capsid. We observe extensive striatal iAb
expression for at least 8 months (the longest postsurgical experi-
mental time point).
HD models
Despite the large number of available HDmouse models, no one
model completely recapitulates the human disease (Ehrnhoefer
et al., 2009). Models of HD induced by viral vectors coding for
mHtt, such as the lentiviral model, exhibit
the striatal MSN loss characteristic of hu-
man HD, which makes these models
very attractive for studying this key as-
pect of the HD phenotype. However,
these animals show only certain motor
deficits and no change in body weight or
survival (de Almeida et al., 2002; Re´gu-
lier et al., 2003).
Transgenic mice expressing N-terminal
mHtt fragments (which are much more
toxic than full-lengthmHtt), such as R6/2
and N171-82Q, exhibit rapid onset of
progressive motor and cognitive deficits,
weight loss, Htt inclusion formation, and
striatal atrophy accompanied by ven-
tricular enlargement, but no loss of
MSNs (Rubinsztein, 2002). These models
are also limited to therapeutic strategies
directed at the N terminus of mHtt, so
they cannot be used to study modifiers of
mHtt toxicity with sites of action outside
of this area such as caspase-6 cleavage
(Graham et al., 2006).
Full-length Htt transgenic models, such
as the YAC128 and BACHD lines, exhibit
more human-like, slower, progressive
cognitive and motor deficits along with
striatal atrophy, ventricular enlargement,
and some loss of MSNs at later stages.
However, unlike in the humandisease, the
YAC128 and BACHD mice gain, rather
than lose, weight during disease progres-
sion (Slow et al., 2003; Van Raamsdonk et
al., 2005; Gray et al., 2008). The back-
ground FVB strain of these models also
undergoes retinal degeneration leading to
blindness, which confounds behavior
testing in older mice (Taketo et al., 1991).
Efficacy of intrabody treatment
Despite the likely utility of iAb gene ther-
apy for neurodegenerative diseases, and the many potential ther-
apeutic iAbs that have been developed for treating Alzheimer’s
disease, Parkinson’s disease, and HD, only one study using iAb
gene therapy for neurodegenerative disease inmice has been pub-
lished. In that study, the anti-Htt iAb EM48 was delivered via
adenovirus to the striatum of R6/2 andN171-82Qmice (Wang et
al., 2008). EM48 treatment reduced neuropil aggregates in the
brains of both models, but had no effect on intranuclear inclu-
sions. This ismost likely due to the fact that, unlikeHapp1, which
distributes freely in cells (Southwell et al., 2008), EM48 is ex-
cluded from the nucleus. EM48 treatment improved both gait
and rotarod performance in 18-week-old N171-82Q mice but
had no effect on body weight or survival. Behavioral assays were
not reported for the R6/2 line. Although promising, these results
suggest thatmore efficacious iAbs, possibly directed against other
Htt epitopes, coupled withmore effective vectors, could improve
therapeutic outcome even further.
Regarding mechanism of iAb action, previous work showed
that both Happ1 and VL12.3 reduce mHtt-induced toxicity and
aggregation in cell culture and brain slicemodels ofHD, although
by different means (Southwell et al., 2008). VL12.3 appears to
Figure9. Happ1 treatment improves bodyweight and survival of N171-82Qmice.A, R6/2miceweigh significantly less thanwt
mice from10weeks of age until death, and there is no effect of iAb treatment. Asterisks indicate a difference betweenGFP-treated
wt and R6/2 mice. B, Happ1-treated N171-82Q mice weigh less than wt littermates, but they also weigh more than GFP-treated
mutants. Asterisks indicate a difference between GFP- and Happ1-treated N171-82Q mice. C, While YAC128 mice trend toward
weighingmore than wtmice, there is no effect of iAb treatment.D, While male BACHDmice weighmore than female mice, there
is no effect of iAb treatment. Asterisks indicate a difference between GFP-treated male and female mice. E, Happ1 treatment has
no effect,while VL12.3 decreases survival of R6/2mice. F, Happ1 treatment increasesmaximumsurvival of N171-82Qmice by 33%
from 30 weeks to 40 weeks of age. *p 0.05, **p 0.01, ***p 0.001.
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prevent aggregation by blocking an epitope required for aggre-
gate seeding (Thakur et al., 2009). On the other hand, the mech-
anism by which VL12.3 prevents mHtt toxicity remains unclear,
as this iAb also causes an increase in nuclear Htt levels, which can
increase toxicity under some circumstances (Saudou et al., 1998;
Hackam et al., 1999; Peters et al., 1999; Schilling et al., 2004).
Conversely, Happ1 has no effect on Htt localization. This iAb
appears to reduce toxicity by increasing clearance of mutant but
not wtHtt. The clearance of soluble mHtt could then lead to
reduced aggregation by a shift in the equilibrium between the
soluble and aggregated state. Reducing soluble mHtt would be
predicted to also decrease the level of oligomeric species of the
mutant protein, which are thought to be responsible for mHtt
toxicity (Bucciantini et al., 2002; Sa´nchez et al., 2003; Behrends et
al., 2006; Kitamura et al., 2006; Takahashi et al., 2008). In fact,
Abs are proving effective for the identification of the particular
conformations of oligomers that are responsible for the toxicity
of amyloid-forming proteins in a variety of diseases (Kayed et al.,
2003; Legleiter et al., 2009).
We find that VL12.3 treatment results in improved behavior
and neuropathology in the lentiviral mouse model of HD. In
transgenic HD models, however, VL12.3 either has no effect or
adverse effects on symptoms. Perhaps the presence of VL12.3
before the introduction of mHtt is required for beneficial effects
of this iAb, and some of the transgenicmodels (particularly R6/2)
develop pathology before the iAb is introduced. Conversely, the
negative effects of VL12.3, i.e., stabilizing soluble mHtt and in-
creasing its nuclear localization (Southwell et al., 2008),may have
detrimental effects in long-term studies.
Happ1 treatment, while equally as beneficial as VL12.3 in the
lentiviralmodel, also improvesmotor and cognitive performance
as well neuropathology in the transgenic models. In the lentiviral
model, Happ1 prevents amphetamine-induced rotation and re-
duces striatal lesion size and intensity, as well as Htt aggregation.
Happ1 also increases body weight and survival of N171-82Q but
not R6/2 mice. The lack of effect in R6/2 may be related to the
extremely early onset and severity of symptoms in this model.
Happ1 treatment improves rotarod and beam-crossing perfor-
mance in all four transgenicmodels. Unlike the other threemod-
els, the improvement in YAC128 motor performance is most
significant at the earliest time points, suggesting a beneficial effect
of Happ1 on the motor task learning deficit of this model (Van
Raamsdonk et al., 2005). A climbing test was performed on the
full-length transgenic models as a way to test motor performance
independent of learning ability, as this behavior is spontaneous
and does not require training. Happ1 treatment increased climb-
ing time of both YAC128 and BACHD mice. Both full-length
transgenic models exhibit anxiety in the open field and deficits in
spatial and cortical learning tasks. Happ1 treatment normalizes
open field exploration in both models and strongly improves
learning in the YAC128 model.
Like VL12.3, Happ1 treatment reduces mHDx-1 aggregates in
the R6/2 model. The similar effect of these iAbs on aggregation is
particularly interesting as Happ1 ameliorates while VL12.3 exac-
erbates the HD behavioral phenotype in these mice. This indi-
cates that, in this case at least, preventing aggregation is not
predictive of therapeutic benefit. There is, however, evidence that
Htt aggregation can be correlated with enhanced neuronal sur-
vival (Arrasate et al., 2004). Unlike VL12.3, Happ1 treatment also
reduces intranuclear inclusions in these mice. This suggests that
intranuclear inclusions may play a greater role in mHtt toxicity
than neuropil aggregates (Hackam et al., 1999; Peters et al., 1999;
Iwata et al., 2009).
Striatal atrophy resulting from neuronal shrinkage and/or
death and concomitant ventricular enlargement is common in
human HD patients as well as the four transgenic models used
in this study.Happ1 treatment decreases ventricular enlargement
in R6/2, YAC128, and BACHD mice. Aggregation and ventricle
size were not assessed in N171-82Q mice as they were used to
study survival and thus killed at the same disease stage rather than
at the same age.
In summary, Happ1 treatment restores normal motor perfor-
mance in N171-82Q, YAC128, and BACHDmice in rotarod and
beam-crossing tests, YAC128 andBACHDmice in climbing tests,
and the lentiviral model in the amphetamine-induced rotation
test. Significant improvement is also seen in R6/2 mice in the
rotarod and beam-crossing tests, as well as N171-82Qmice in the
clasping test (summarized in Fig. S6, available at www.jneurosci.
org as supplemental material). Happ1 treatment also restores
normal cognitive performance in Yac128 and BACHD mice in
open field tests and in Yac128 mice in novel object location and
novel object preference tests. Although learning deficits were de-
tected in BACHDmice by these tests, there is no effect of Happ1
treatment (summarized in Fig. S7, available atwww.jneurosci.org
as supplemental material). Happ1 treatment dramatically re-
duces striatal neuron loss in the lentiviral model, Htt aggregation
in the lentiviral and R6/2models, and normalizes ventricle size in
R6/2, YAC128, and BACHDmice (summarized in Fig. S8, avail-
able at www.jneurosci.org as supplemental material). While
Happ1has no effect onR6/2, YAC128, or BACHDbodyweight or
R6/2 survival, it does significantly increase both body weight and
life span of N171-82Q mice.
The highly beneficial effects ofHapp1 treatment on numerous
aspects of the HD phenotype in all five mouse models of HD
supports the idea that therapies directed at the specific degrada-
tion of mHtt represent a selective and effective strategy for the
treatment of HD, with a very low probability of off-target effects.
This approach can, however, still be improved. Although cur-
rently the most efficacious anti-Htt iAb in vivo, Happ1 does not
completely prevent HD symptoms in mice. The therapeutic ben-
efits of Happ1 most likely derive from increased clearance of
mHtt as a result of Happ1 binding. Re-engineering to increase
stability and binding efficiency, as was done with VL12.3 (Colby
et al., 2004), could increase clearance of mHtt and subsequently
increase the degree of disease prevention.
Another therapeutic approach directed at reducing levels of
mHtt is gene silencing. AAV-mediated striatal silencing of both
wt and mHtt RNAs in N171-82Q mice results in significantly
enhanced motor performance as well as improved survival, but
no effect on body weight loss (Boudreau et al., 2009). Although
no detrimental effects have been observed thus far as a result of
decreased wtHtt expression in these mice, side effects caused by
loss of wtHtt function remain a possibility in human patients due
to the extended time frame that would be required for suppress-
ing mHtt expression. Importantly, allele-specific silencing of
mHtt has been achieved in cellularmodels ofHDeither by the use
of SNPs, which would be effective only for the portion of the
affected population with the appropriate haplotype (Pfister et al.,
2009; Warby et al., 2009), or by single stranded oligomers target-
ing expanded CAG, which would only be effective for HD pa-
tients with a significant repeat difference between disease and wt
alleles (Hu et al., 2009). Nonetheless, like iAb-induced mHtt re-
duction, gene silencing is a therapeutic strategy with a great deal
of potential.
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